Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer

530 - Predictive role of stromal tumor infiltrating lymphocytes (TILs) in patients with metastatic HER2-positive breast cancer (BC) treated with trastuzumab


20 Dec 2015


Breast cancer


Changhoon Yoo


Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519


C. Yoo1, J. Yoon1, H.J. Lee1, J. Ahn1, K.H. Jung2, G. Gong1, S.B. Kim1

Author affiliations

  • 1 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 University Of Ulsan College Of Medicine, Asan Medical Center, 138-736 - Seoul/KR

Abstract 530


Prognostic significance of stromal TILs in metastatic BC has been suggested in various BC subtypes. However, predictive role of stromal TILs for the efficacy of trastuzumab has not been established in patients with HER2-positive BC. This study was performed to evaluate whether the stromal TILs are associated with the efficacy of trastuzumab in patients with metastatic HER2-positve BC.


Between June 2006 and March 2013, a total of 60 women with recurrent or metastatic HER2-positive BC treated with trastuzumab were included. Trastuzumab was administered either as single agent or combination with taxanes. Stromal TILs were assessed using immunohistochemistry in surgical specimen (n = 39, 65%) and biopsy specimen of metastatic lesion (n = 21, 35%). Primary endpoint of this study was progression-free survival (PFS), and secondary endpoints were response rate and overall survival (OS).


Median age was 54 year old (range, 36-76), and all patients had invasive ductal carcinoma. Hormone receptor was positive in 34 patients (57%) and 18 patients (30%) initially presented with metastatic disease. Nine patients (15%) received cytotoxic chemotherapy without trastuzumab before the administration of trastuzumab. Patients were grouped according to the TILs (< 10% [n = 50] and >10% [n = 10]), and there was no significant difference in age (p = 0.68), histologic grade (p = 1.00), metastatic sites (p > 0.05), and number of lines of chemotherapy before the administration of Herceptin (p = 0.33) among patients with low and high stromal TILs. High TILs were more common in hormone receptor-negative tumor compared with –positive tumor (31% vs 6%; p = 0.02). Median PFS in patients with high stromal TILs were longer than that in those with low TILs (22.0 months [95% CI, 9.6-34.4] vs 14.0 months [95% CI, 9.6-18.4]). However, this was marginally significant (p = 0.057). There was no difference in response rates (p = 0.43) and OS (p = 0.94) according to the stromal TILs.


This study suggests that the stromal TILs might be associated with the clinical outcomes of HER2-targeted therapy in patients with metastatic HER2-positive BC. Further validation is necessary.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings